Background
Methods
Subjects and tissue samples
Experimental procedure
Data analysis
Post-hoc analysis
Quantification of candidate gene expression by real time RT-PCR
Results
Parameter | Estimate | |
---|---|---|
Per chip | Per cent | |
Number of probes
| 41000 | |
(genes) | (29421) | |
Number of hybridized probes (genes)
a
| ||
Eutopic | 35646 | 87 |
(25987) | (88) | |
Ectopic | 35587 | 87 |
(26222) | (89) | |
Number of high expressed probes (genes)
b
| ||
Eutopic | 23267 | 65 |
(19168) | (74) | |
Ectopic | 15912 | 45 |
(13681) | (52) |
Differential expression (DE)
Description of comparison (Number of genes) | Gene in enriched category (Gene symbol) | Enriched pathways | (p-value) |
---|---|---|---|
Eutopic-to-ectopic
| ERBB3 | Activation of astroglia proliferation | (0) |
Stage 3 & Stage 4 (3)b | CDK5 mediated cell death and survival | (0) | |
Proliferative & Secretory (4)b | ERBB family signaling | (0) | |
Membrane bound ESR1 interaction with growth factor signaling | (<0.01) | ||
Ligand-independent activation of ESR1 and ESR2 | (<0.01) | ||
ERBB3, LAMC2 | Alpha6/beta-4 integrins in carcinoma progression | (<0.01) | |
Stages 3-to-4
| STAT2 | Immune response involving IL-15 and IFN signaling | (<0.02) |
Eutopic & Ectopic (50)c | |||
Proliferative-to-Secretory
| Angiotensin signaling via STATs | (<0.03) | |
Eutopic & Ectopic (4)d | NOS1AP | nNOS signaling in neuronal process | (<0.03) |
AP1B1 | Immune response involving regulation of T cell function by CTLA-4 | (<0.04) | |
SOCS5 | Immune response involving IL-4 signaling | (<0.04) | |
GOT2 | GABA biosynthesis and metabolism | (<0.05) |
Specific analysis |
Nature of differential change [Number of genes]
| Top enriched pathways | [Gene symbol(s) of major candidate(s)] | (p-value) |
---|---|---|---|---|
Pooled
|
Up-regulated [50]
| WNT signaling | [NRCAM, WNT16] | (0) |
DNA damage-induced responses and apoptosis | [CHEK1] | (<0.01) | ||
Role of 14-3-3 proteins in cell cycle regulation | [CHEK1] | (<0.02) | ||
Cadherins mediated cell adhesion | [CHP] | (<0.03) | ||
Endothelial cell contacts by non-junctional mechanisms | [CHP] | (<0.03) | ||
Role of SCF complex in cell cycle regulation | [CHEK1] | (<0.03) | ||
ATM/ATR regulation of cell cycle | [CHEK1] | (<0.04) | ||
nNOS signaling in neuronal synapses | [RASD1] | (<0.03) | ||
Activation of astroglial cell proliferation by ACM3 | [ERBB3] | (<0.04) | ||
G-protein signaling in RhoA regulation pathway | [ARHGAP26] | (<0.04) | ||
CDK5 in apoptosis and survival | [ERBB3] | (<0.04) | ||
ERBB-family signaling | [ERBB3] | (<0.05) | ||
Regulation of ElF2 activity associated with translation | [CSNK1G1] | (<0.05) | ||
Ligand-independent activation of ESR1 and ESR2 | [ERBB3] | (<0.05) | ||
Non-genomic action of androgen receptor | [WNT16] | (<0.05) | ||
Down-regulated [41]
| Regulation of glucose and lipid metabolism | [APOE] | (0) | |
GDNF signaling | [ITGB1] | (<0.04) | ||
Immune response involving antigen presentation by MHC class I | [HLA-C] | (0.05) | ||
Chemotaxis involving CCR4-induced leukocyte adhesion | [ITGB1] | (<0.05) | ||
Stage 3
|
Up-regulated [4]
| No specific enriched category identified | ||
Down-regulated [48]
| Cytoskeleton remodeling involving RalB and RalA regulation pathway | [RALGDS] | (<0.01) | |
Clathrin coated vesicle formation | [MYO1D] | (<0.02) | ||
Transcriptional silencing involving HP1 family | [PFDN5] | (<0.02) | ||
G-protein signaling involving interaction among Ras-family GTPases and K-RAS/N-RAS/H_RAS regulation pathway | [RALGDS] | (<0.03) | ||
Stage 4
|
Up-regulated [31]
| Cell contraction involving relaxin and GPCRs | [ADCY6, EDNRA, RXFP1] | (0) |
Development involving endothelin-1/EDNRA signaling | [ADCY6, EDNRA] | (0) | ||
DNA damage induced apoptosis and DNA repair | [NBN] | (<0.01) | ||
Beta-2 adrenergic dependent CFTR expression | [ADCY6] | (<0.01) | ||
Regulation of lipid metabolism | [PPARA] | (<0.02) | ||
Alpha-1 adrenergic receptor signaling | [ADCY6] | (<0.02) | ||
Mu- and kappa-type opioid receptor mediated physiological process | [ADCY6] | (<0.03) | ||
Mucin expression via IL-6, IL-17 signaling pathways | [TRAF3IP2] | (<0.04) | ||
G-protein signaling | [ADCY6] | (<0.04) | ||
Down-regulated [3]
| Transport from Golgi and ER to the apical membrane | [PPIA] | (0) | |
Intracellular cholesterol and sphingolipids transport | [PPIA] | (<0.01) | ||
Proliferative phase
|
Up-regulated [109]
| RAS regulation pathway | [BCR, RASGRF1] | (0) |
TC21 regulation pathway | [BCR, RASGRF1] | (0) | ||
Regulation of CDC42 activity | [BCR, FGFR1] | (<0.01) | ||
Sin3 and NuRD mediated transcription regulation | [CHD3, SIN3A] | (<0.01) | ||
GDNF family signaling | [GFRA2, NRTN] | (<0.01) | ||
Phospholipid metabolism | [GPD2, NRTN] | (<0.02) | ||
Immune response involving CD40 signaling | [IRF1, TRAF3IP2] | (<0.02) | ||
Down-regulated [20]
| Cytoskeleton remodeling involving α-1A adrenergic receptor | |||
Dependent inhibition of PI3K and regulation of actin by Rho GTPases | [LAMB1, MYL12B] | (<0.01) | ||
Cell contraction involving δ-type opioid receptor, S1P2 receptor, ACM | [MYL12B] | (<0.01) | ||
Development associated MAG dependent inhibition of neurite outgrowth | [MYL12B] | (<0.01) | ||
Development associated with TGF-beta dependent induction of EMT via RhoA, PI3K and ILK | [TPM1] | (<0.01) | ||
Cell adhesion involving histamine H1 receptor | [MYL12B] | (<0.01) | ||
Cell adhesion and chemotaxis involving integrin | [LAMB1, MYL12B] | (<0.01) | ||
Chemotaxis involving inhibitory action of lipoxins on IL-8 and leukotriene B4-induced neutrophil migration | [MYL12B] | (<0.01) | ||
GPCRs in platelet aggregation | [MYL12B] | (<0.02) | ||
Immune response involving CCR3 signaling in eosinophils | [MYL12B] | (<0.02) | ||
Oxidative phosphorylation | [UQCR11] | (<0.03) | ||
Secretory phase
|
Up-regulated [17]
| Transport involving RAN regulation pathway | [TNPO1] | (<0.01) |
Immune response involving MIF-JAB1 signaling | [PGR] | (<0.01) | ||
nNOS signaling in neuronal synapses and circadian rhythm | [RASD1] | (<0.02) | ||
Cell cycle associated spindle assembly and chromosome separation | [TNPO1] | (<0.02) | ||
Regulation of lipid metabolism | [TNPO1] | (<0.02) | ||
Regulation of glycogen metabolism | [AGL] | (<0.02) | ||
Progesterone mediated maturation | [PGR] | (<0.02) | ||
Cell adhesion associated ECM remodeling | [MME] | (<0.03) | ||
TGF-beta receptor signaling in development | [TNPO1] | (<0.03) | ||
Down-regulated [122]
| Cell contraction involving δ-type opioid receptor | [MYL9] | (0) | |
Development associated Slit-Robo signaling | [DPYSL2, ROBO3] | (<0) | ||
Insulin mediated regulation of translation | [ElF4EBP1, PPP1CC] | (<0.01) | ||
Leukotriene 4 biosynthesis and metabolism | [GGT5, LTA4H] | (<0.01) | ||
Chemotaxis involving inhibitory action of lipoxins on IL-8 and leukotriene B4-induced neutrophil migration | [MYL9, RAC2) | (<0.01) | ||
Endoplasmic reticulum stress response pathway | [ATF4, PPP1CC] | (<0.01) | ||
Immune response involving CCR3 signaling in eosinophils | [MYL9, RAC2] | (<0.03) | ||
GTP-XTP metabolism | [GUK1, NME3, POLR3H] | (<0.03) | ||
Cytoskeleton remodeling via RalB regulation pathway | [RALGDS] | (<0.04) | ||
Eutopic
|
Up-regulated [182]
| Cytoskeleton remodeling involving ACM3 and ACM4 | [CHRM4, GNAQ] | (0) |
G-protein signaling involving regulation of cAMP levels by ACM | [CHRM4, GNAQ] | (0) | ||
Transcription involving Tubby signaling and HP1 family | [GNAQ] | (0) | ||
Regulation of lipid metabolism involving G-alpha(q) regulation | [GNAQ, PTGS2] | (0) | ||
Cell contacts by non-junctional mechanisms | [ITGA5, MAG1, PECAM1] | (<0.01) | ||
NMDA –dependent neurophysiological process | [GNAQ, GRIN2A] | (<0.01) | ||
Cell cycle at metaphase check point | [CBX3, INCENP] | (<0.01) | ||
G-protein signaling involving Rap1A regulation pathways | [MAGI1, RAPGEF1] | (<0.02) | ||
Regulation of translation through EIF4F activity | [EIF4A2] | (<0.03) | ||
Regulation of translation by alpha-1 adrenergic receptors | [EIF4A2, GNAQ] | (<0.03) | ||
Development involving endothelin-1/EDNRA signaling | [GNAQ, NPPB] | (<0.03) | ||
Cytoskeleton remodeling via FAK signalin | [GNAQ, RAPGEF1] | (<0.04) | ||
Immune response involving PGE2 common pathways | [GNAQ, PTGS2] | (<0.03) | ||
Immune response involving IL-17 signaling pathways | [CXCL3, PTGS2] | (<0.04) | ||
Cell contraction via oxytocin signaling | [GNAQ, PTGS2] | (<0.04) | ||
Transcription via PPAR pathway | [MED1, PTGS2] | (<0.04) | ||
Regulation of lipid metabolism through alpha-1 adrenergic receptors signaling via arachidonic acid | [GNAQ, PTGS2] | (<0.05) | ||
Down-regulated [48]
| Cell cycle regulation involving SCF complex | [CDC34, NEDD8, UBA52] | (0) | |
p53 regulation involving SUMO | [UBA52] | (<0.02) | ||
Regulation of degradation and traffic of CFTR | [DYNLL1, UBA52] | (<0.02) | ||
WNT signaling pathway involving degradation of bete-catenin | [UBA52] | (<0.03) | ||
Transcriptional silencing involving HP1 family | [PFDN5] | (<0.03) | ||
Immune response involving IL-12 and MIF-JAB1 signaling pathways | [UBA52] | (<0.03) | ||
Angiotensin signaling via beta-arrestin | [CLTA, UBA52] | (<0.03) | ||
ATM/ATR regulation of G1/S and G2/M checkpoints | [UBA52] | (<0.04) | ||
NGF signaling for apoptosis and survival | [EPB41L1] | |||
and activation of NF-kB | [UBA52] | (<0.04) | ||
Neurophysiological process involving GABA-A receptor life cycle | [CLTA] | (<0.04) | ||
Regulation of translation initiation | [EIF1, RPL7, RPL12, RPL15, RPL21, RPL22, RPL29, RPS3A, RPS10, RPS14, UBA52] | (<0.04) | ||
Transition and termination of DNA replication | [UBA52] | (<0.04) | ||
Activin A signaling regulation | [UBA52] | (<0.05) | ||
Ectopic
|
Up-regulated [665]
| Beta-2 adrenergic-dependent CFTR expression | [ADCY2, ADRB3, CREB1, PRKAR1B, PRKAR2B] | (0) |
Mu-type opioid receptor mediated neurophysiological process | [ADCY2, ADCY5, CREB1, HPCA, PRKAR1B, PRKAR2B] | (0) | ||
Development involving alpha-1 and beta-adrenergic receptors signaling via cAMP and PIP3 signaling | [ADCY2, ADCY5, AKT3, CREB1, FOXO3, GAB1, PRKAR1B, PRKAR2B, YWHAE] | (0) | ||
Cell adhesion involving ephrin signaling | [ADAM10, EFNA5, EPHA4, EPHB6] | (0) | ||
Transport involving RAB3 regulation pathway | [DMXL2, RAB3B] | (0) | ||
Neurophysiological process involving corticoliberin signaling via CRHR1 | [ADCY2, ADCY5, CACNA1C, CREB1, PRKAR2B, IVL] | (0) | ||
Signal transduction involving cAMP and PKA signaling | [ADCY2, ADCY5, CACNA1C, CREB1, PRKAR1B, PRKAR2B, PCTK1] | (0) | ||
G-protein signaling involving G-Protein beta/gamma signaling cascades | [ADCY2, ADCY5, AKT3, PRKAR1B, PRKAR2B] | (0) | ||
G-protein signaling involving RhoA regulation pathway | [ARHGEF2, EFNA5, EPHA4, MCF2L] | (0) | ||
eNOS activity in cell contraction | [ADCY5, CACNA1C, PRKAR1B,PRKAR2B, PRKG1] | (0) | ||
MAG-dependent inhibition of neurite outgrowth | [NGFR, PSEN2, RASGRF1] | (0) | ||
Neurophysiological process involving delta-type opioid receptor | [ADCY2, CREB1, HPCA, PRKAR1B, PRKAR2B] | (<0.01) | ||
Neurophysiological process involving HTR1A receptor signaling | [ADCY2, ADCY5, HPCA, HTR1A, PRKAR1B, PRKAR2B] | (<0.01) | ||
Neurophysiological process involving melatonin signaling | [ADCY2, ADCY5, CREB1, PRKAR1B, PRKAR2B, RORA] | (<0.01) | ||
Neurophysiological process involving dopamine D2 receptor signaling | [ADCY2, ADCY5, CACNA1C, PRKAR1B, PRKAR2B] | (<0.01) | ||
Neurophysiological process in circadian rhythm | [ADCAY1, CLOCK, CREB1, CACNA1C, RORA] | (<0.01) | ||
Alpha-2 adrenergic receptor regulation of ion channels | [ADCY5, AKT3, CACNA1C, PRKAR1B, PRKAR2B] | (<0.01) | ||
NGF signaling pathway in apoptosis and survival | [AKT3, CAD, GAB1] | (<0.01) | ||
Transcription involving CREB pathway | (<0.01) | |||
Role of activin A in cell differentiation and proliferation | [ADCY2, ADCY5, CREB1, NR5A1/SF1, PRKAR1B, PRKAR2B] | (<0.01) | ||
GH-RH signaling | [ADCY2, ADCY5, CACNA1C, CREB1, PRKAR1B, PRKAR2B] | (<0.01) | ||
ZNF202 in regulation of expression of genes involved in atherosclerosis | [ADRB3, APOL2, LPL] | (<0.01) | ||
Regulation of lipid metabolism by niacin and isoprenaline | [ADCY2, ADCY5, ADRB3, PRKAR1B, PRKAR2B] | (<0.01) | ||
Ligand-independent activation of ESR1 and ESR2 | [ADCY2, ADCY5, AKT3, PRKAR1B, PRKAR2B] | (<0.01) | ||
Relaxin signaling pathway | [ADCY5, AKT3, CREB1, PRKAR1B, PRKAR2B] | (<0.01) | ||
Melanocyte development and pigmentation | [AKT3, CREB1, PRKAR1B, PRKAR2B, PRKG1] | (<0.01) | ||
Down-regulated [18]
| Immune response involving antigen presentation by MHC class I | [PDIA3] | (<0.01) | |
Vitamin B6 metabolism | [PHPT1] | (<0.02) | ||
Blood coagulation and platelet degranulation | [F13A1] | (<0.03) | ||
Cholesterol and sphingolipids intracellular transport | [PPIA] | (<0.03) | ||
GSL metabolism | (<0.05) | |||
Eutopic
|
Up-regulated [19]
| Cell cycle at initiation of mitosis and regulation of G1/S transition | [LMNB2, PPP2R3A] | (<0.01) |
Dopamine D2 receptor transactivation of PDGF receptor | [PPP2R3A] | (<0.01) | ||
Apoptosis and survival involving caspase cascade, FAS signaling cascade and HTR1A signaling and anti-apoptosis by external signals via NF-kB | [LMNB2, PPP2R3A] | (<0.01) | ||
G-protein signaling involving regulation CDC42 activity | [ARHGAP17] | (<0.01) | ||
Gultamate regulation of Dopamine D1A receptor signaling | [PPP2R3A] | (<0.01) | ||
PKA signaling | [PPP2R3A] | (<0.02) | ||
Down-regulated [56]
| Translation involving regulation of ElF2 | [PPP1CC] | (0) | |
DNA damage involving NHEJ mechanisms of DSBs repair | [CSNK2A2] | (<0.02) | ||
Cytoskeleton remodeling involving activin A | [FNTA] | (<0.02) | ||
Olfactory transduction | [OR2H1] | (<0.02) | ||
Cell cycle involving chromosome condensation in prometaphase, sister chromatic cohesion, regulation of S phase and initiation of mitosis | [HIST1H1C] | (<0.03) | ||
Cadherin mediated cell adhesion | [PTPRF] | (<0.03) | ||
GABA-A receptor mediated neurophysiological process | [PPP1C] | (<0.03) | ||
MAG-dependent inhibition of neurite outgrowth | [MAG] | (<0.05) | ||
Cell adhesion via PLAU signaling | [CSNK2A2] | (<0.05) | ||
Ectopic
|
Up-regulated [0]
| |||
Down-regulated [91]
| G-protein signaling involving Rap2A regulation pathway and G-protein alpha-s signaling cascade | [PRKAR2B, RAPGEF3] | (0) | |
Glycolysis and gluconeogenesis | [ENO2] | (0) | ||
cAMP-Ca+2-dependent signal transduction | [PRKAR2B, RAPGEF3] | (<0.01) | ||
G protein mediated regulation of MAPK-ERK signaling | [PRKAR2B, RAPGEF3] | (<0.01) | ||
Development involving MAG, PACAP signaling, activin A, A2A and A2B receptor signaling and Hedgehog signaling | [MYH14, NANOG, NTF3, PRKAR2B, RAPGEF3] | (<0.01) | ||
Regulation of eNOS activity | [PRKAR2B] | (<0.01) | ||
CCR3 signaling in eosinophils | [FGR, MYH14] | (<0.02) | ||
NMDA dependent neurophysiological process | [PRKAR2B, RAPGEF3] | (<0.03) | ||
(<0.03) | ||||
CFTR expression, maturation and activity | [HSPA6, PRKAR2B] | (<0.03) |
K-mean clusters and differential co-expression (DC)
Cluster identity (Total number of genes) [Number of genes with differential display: Up-regulated/Down-regulated] | |
---|---|
Enriched category (p-value) | Gene symbols of major candidate genes (Vector of differential) |
Cluster 1, K1 (3210) [208: 120/88]
| |
Cell cycle (<0.01) | CCNB1, CDC45L, CENPF, NCAPD3, RAD51 (up); |
CCND2, MYL9, ORC6L, TNPO1 (down) | |
IGF-1 receptor signalling (<0.01) | IGF2 (up), IGFBP5, CCND2 (down) |
Cytoskeleton remodelling involving regulation of actin (<0.02) | MYH9, MYL9 (down) |
O-glycan biosynthesis (<0.02) | GALNT1, GALNT7 (down) |
Immune response(<0.02) | PGR (up), CCND2 (down) |
G-protein signalling in TC21 regulation pathway (<0.02) | RRAS2 (up), RASGRP2 (down) |
DNA damage (<0.03) | NBN, RAD51 (up), CCND2 (down) |
Neurite outgrowth (<0.05) | MYH9, MYL9 (down) |
Regulation of glucose and lipid metabolism (<0.05) | CYP51A1, FOXA (up), TNPO1 (down) |
G-protein signalling in Rap1 regulation pathway (<0.05) | KRIT1 (up), RASGRP2 (down) |
Progesterone action (<0.05) | CCNB1, PGR (up) |
Signal transduction: | |
Erk interactions (<0.04) | DUSP4 (up) |
AKT signaling (<0.05) | HSP90AA1 (up), CCDD2 (down) |
Cluster 2, K2 (8194) [148: 0/148]
| |
Immune response (0) | ACTG1, C3, C4B, C1QB, HLA-C, PTPN11/SHP2 (down) |
Cell adhesion (0) | ACTG1, ITGB1, PTPN11/SHP2 (down) |
Regulation of CFTR (0) | ACTG1, HSPA8, PSMB1, TSG101, UBC (down) |
Signal transduction involving activin A signalling regulation (0) | BAMBI, H3F3A, UBC (down) |
Slit-Robo signaling (<0.01) | ACTG1, ROBO3 (down) |
Cytoskeletal remodelling (<0.01) | ACTG1, DSTN, RALGDS (down) |
Glutathione metabolism (<0.01) | GSTM5, MGST3 (down) |
Chemotaxis (<0.02) | ACTG1, GNG4, ITGB1 (down) |
Apoptosis and survival (<0.02) | HSPA8, ACTG1 (down) |
Glucose and lipid metabolism (<0.03) | APOE (down) |
Neurite outgrowth (<0.03) | ACTG1, DSTN (down) |
N-glycan biosynthesis (<0.04) | GALT, GANAB (down) |
Cluster 3, K3 (6078) [102: 102/0]
| |
Differentiation (0) | PRKCG (up) |
Transcriptional regulation of amino acid metabolism (0) | MAX, PRKCG (up) |
Androgen receptor nuclear signaling (<0.01) | NCOA2/GRIP1, WNT16 (up) |
Neurophysiological process associated with PGE2-induced pain processing (<0.01) | GLRA3 (up) |
Gene-set enrichment analysis (GSEA)
BROAD gene sets (Set description) | ||
---|---|---|
Cluster identity | Number of selection (set identity; p value; qFDR; NES) | Total number of genes1; number of genes in classified gene families1,2 |
C1 (Cytogenetics)
| ||
K1 | 0 | |
K2 | 0 | |
K3 | 0 | |
K4 | 1 (Chr4q12; 0; 0.11; 1.8) | 47; 6 (Cgf); 1 (Ong); 2 (Tf) |
C2 (Functional)
| ||
K1 | 0 | |
K2 | 0 | |
K3 | 0 | |
K4 | 0 | |
C3 (Regulatory motif)
| ||
K1 | 1 (RRCCGTTA_UN; 0; 0.25; -1.8); | 55; 1 (Cgf); 2 (Cdm); 2 (Ong); 3 (Pk); 11 (Tf) |
K2 | 1 (V$AP4_q6; 0; 0.05; −2.0) | 173; 1 (Cdm); 9 (Cgf); 7 (Hdp); 9 (Ong); 11(Pk); |
34 (Tf); 1 (Ts) | ||
K3 | 0 | |
K4 | 1 (GCAAGA,MIR-431; 0; 0.04; 1.9) | 39; 1 (Cdm); 2 (Cgf); 1 (Hdp); 2 (Ong); 1 (Pk); 6 (Tf); 2 (Ts) |
C4 (Cancer gene neighborhood)
| ||
K1 | 2 (MORF_MYC; (0; 0.00; 2.3) | 72; 1 (Cdm); 2 (Cgf); 5 (Hdp); 5 (Onc); 4 (Pk); 14 (Tf) |
(MORF_ESR1; 0; 0.04; 2.0) | 160; 3 (Cdm); 7 (Cgf); 7 (Hdp); 8 (Ong); 9 (Pk); 36 (Tf); 3 (Ts) | |
K2 | 0 | |
K3 | 0 | |
K4 | 2 (MORF_RAD23B; 0; 0.18; 1.8) | 164; 1 (Cgf); 2 (Ong); 1 (Pk); 8 (Tf); 2 (Ts) |
(GNF2_CCNA2; 0.02; 0.23; 1.8) | 62; 1 (Cdm); 6 (Pk); 3 (Tf); 1 (Ts) | |
C5 (Gene ontology)
| ||
K1 | 0 | |
K2 | 0 | |
K3 | 0 | |
K4 | 2 (PATTERN_ BINDING; 0; 0.07; 2.1) | 45; 2 (Cdm); 6 (Cgf); 1 (Tf) |
(POLYSACCHARIDE_BINDING; 0; 0.18; 1.9) | 36; 6 (Cgf); 1 (Tf) |
Expressional cohort of marker genes
Expression characteristics | ||
---|---|---|
Gene symbol (GenBank ID) [Gene name] | Fold changea | |
Microarrayb | RT-PCRc | |
Up-regulated in eutopic tissue
| ||
General | ||
3HMGN2 (NM_005517) | 4.8+1.0 | 2.4++0.3 |
[High-mobility group nucleosomal binding domain 2]
| ||
MKI67 (NM_002417 ) | 3.4+0.9 | 4.6+1.8 |
[Ki-67-like antigen]
| ||
NRCAM (NM_001037132) | 4.5+1.6 | 2.1+0.5 |
[Neuronal cell adhesion molecule]*
| ||
PARG (NM_003631) | 3.8+2.1 | 3.4+1.5 |
[Poly (adp-ribose) glycohydrolase]
| ||
TMPO (NM_001032283) | 3.1+1.9 | 2.8+1.1 |
[Thymopoietin]
| ||
Stage 3 | ||
ATP2A2 (NM_001681) | 5.1+1.9 | 8.6+3.5 |
[ATPase, Ca++ transporting, cardiac muscle,slow twitch 2]
| ||
CHIA (NM_021797) | 3.4+1.3 | 7.3+1.5 |
[Chitinase, acidic]
| ||
DAPK2 (NM_014326) | 6.2+2.3 | 9.7+1.8 |
[Death-associated protein kinase 2]*
| ||
ERC1 (NM_178040) | 6.8+1.5 | 10.8+3.0 |
[Elks/rab6-interacting family member 1]*
| ||
TACC2 (NM_206862) | 13.7+3.2 | 6.4+2.0 |
[Transforming, acidic coiled-coil containing protein 2]
| ||
ZBTB22 (NM_005453) | 5.2+2.7 | 12.3+3.1 |
[Zinc finger and BTB domain containing 22]*
| ||
Proliferative phase | ||
BAG5 (NM_001015049) | 4.2+1.9 | 6.5+4.1 |
[Bcl2-associated athanogene 5]
| ||
CDCA3 (NM_031299) | 3.9+1.5 | 9.9+6.6 |
[Cell division cycle associated 3]
| ||
EGR3 (NM_004430) | 3.7+1.0 | 5.3+1.4 |
[Early growth response 3]*
| ||
FGFBP1 (NM_005130) | 5.7+2.1 | 7.3+2.7 |
[Fibroblast growth factor binding protein 1]
| ||
TPM3 (NM_001043352) | 3.4+1.9 | 6.3+3.4 |
[Tropomyosin 3]
| ||
Secretory phase | ||
DHRS3 (NM_004753) | 3.6+1.7 | 5.9+1.9 |
[Dehydrogenase/reductase (SDR family) member]
| ||
Up-regulated in ectopic tissue
| ||
General | ||
BAP1 (NM_004656) | 12.6+3.3 | 13.9+3.4 |
[BRCA1 associated protein-1]*
| ||
CBLL1 (NM_024814) | 6.2+2.5 | 6.1+2.5 |
[Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1]
| ||
CLOCK (NM_004898) | 9.0+2.6 | 5.3+0.6 |
[Clock homolog (mouse)]*
| ||
EPB41L1 (NM_012156) | 3.1+1.6 | 2.6+1.2 |
[Erythrocyte membrane protein band 4.1-like 1]
| ||
LPL (NM_000237) | 5.5+2.9 | 7.2+2.9 |
[Lipoprotein lipase]
| ||
PPAT (NM_002703) | 5.8+2.9 | 5.6+3.4 |
[Phosphoribosyl pyrophosphate amidotransferase]
| ||
SCAMP1 (NM_004866) | 10.5+3.2 | 6.0+2.6 |
[Secretory carrier membrane protein 1]
| ||
SFRS1 (NM_001078166) | 8.7+3.6 | 6.6+2.2 |
[Splicing factor, arginine/serine-rich 1]
| ||
USP46 (NM_022832) | 4.0+1.8 | 3.7+1.1 |
[Ubiquitin specific peptidase 46]
| ||
YWHAE (NM_006761) | 3.4+2.7 | 3.3+1.8 |
[Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon]
| ||
ZNF644 (NM_201269) | 4.4+1.0 | 5.1+2.9 |
[Zinc finger protein 644]
|